Abzena's AIM

Abzena Ltd. is following in the footsteps of other revenue-generating U.K. biopharma service companies by seeking a listing on the LSE's AIM market. CEO John Burt told BioCentury the listing will provide the company enough cash to grow both organically and through bolt-on acquisitions.

Abzena was formed last year through the merger of two biologics services companies: PolyTherics Ltd. and Antitope Ltd. Burt said the pair provide complementary services: PolyTherics offers its ThioBridge site-specific antibody-drug conjugation technology along with various tools to optimize therapeutic properties of biopharmaceuticals. Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunized therapeutic proteins, and manufacturing cell line development...